<DOC>
	<DOCNO>NCT01044108</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial investigate safety , tolerability , efficacy pharmacokinetics ( rate trial drug eliminate body ) NNC 0070-0002-0453 overweight/obese , otherwise healthy male female volunteer . Selected subject continue follow-up period 5 year .</brief_summary>
	<brief_title>A Two Part Trial Investigating Anti-obesity Drug Overweight/Obese Male Female Healthy Volunteers</brief_title>
	<detailed_description>Due unfavourable benefit-risk profile observe phase 1 trial obesity project , NN9161 , Novo Nordisk decide terminate clinical development .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<criteria>FOR TRIAL PART 1 , THE FOLLOWING APPLIES : Informed consent must obtain trialrelated activity . Trialrelated activity procedure would perform normal management subject Overweight/obese male : Body Mass Index ( BMI ) 27.0 39.0 kg/m2 Good general health FOR TRIAL PART 2 , THE FOLLOWING APPLIES : Informed consent must obtain trialrelated activity . Trialrelated activity procedure would perform normal management subject . Obese male female subject : Body Mass Index ( BMI ) 30.0 39.0 kg/m2 Good general health . Aggressive diet attempt within last 3 month Current history treatment medication may cause significant weight gain History major depressive disorder history suicide attempt history suicidal behaviour History eat disorder Any weight change 5 kg ( 11 pound ) last 3 month Tobacco use History alcoholism drug/chemical abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>